Back to Authors

Patnaik, Mrinal M.

https://orcid.org/0000-0001-6998-662X

A5072463255 | I1330342723

Mayo Clinic

Citations 648

Genomic and Transcriptional Profiling Stratifies Vq Myeloma Lines into Two Clusters with Distinct Risk Signatures and Drug Responses

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9935-9936

10.1182/blood-2022-162827

Response Rates to Venetoclax Based Therapies in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12238-12240

10.1182/blood-2022-165470

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2887-2890

10.1182/blood-2022-162367

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias of Undetermined Significance

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2893-2894

10.1182/blood-2022-165163

Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9735-9736

10.1182/blood-2022-163450

Prevalence and Impact of Clonal Hematopoiesis in Therapy Related Myeloid Neoplasms Occurring in the Context of Low-Grade Follicular Lymphoma Treated with Radioisotope Therapy

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 11403-11405

10.1182/blood-2022-165124

Monocytopenia As an Adverse Prognosticator in Vexas Syndrome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 11406-11407

10.1182/blood-2022-165706

U2AF1 Mutant Clonal Hematopoiesis Is Infrequent, Context Dependent, and Commonly Co-Occurs with BCOR Mutations

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 11408-11409

10.1182/blood-2022-166794

DNMT3A/TET2 Mutant Clonal Hematopoiesis in Vexas Syndrome Results in DNA Hypomethylation and Transcriptional Activation of WT1 and MPL Oncogenic Pathways

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 11410-11411

10.1182/blood-2022-167359

Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6962-6963

10.1182/blood-2022-167978